Methocarbamol Use in Pediatric Patients

Introduction to Methocarbamol

Methocarbamol lacks FDA approval for pediatric use, with no established safety or efficacy data in children under 16 years 1
The American Academy of Pediatrics and other guideline societies may have recommendations, but methocarbamol's mechanism of action as a centrally acting skeletal muscle relaxant is unclear, and it does not act directly on skeletal muscle 1

Methocarbamol causes significant central nervous system adverse effects including drowsiness, dizziness, and sedation 1
Cardiovascular effects include bradycardia and hypotension, which may be particularly concerning in pediatric patients 1
Drug elimination is significantly impaired in patients with liver and kidney disease, requiring careful consideration of organ function 1
The drug should not be used in patients with myasthenia gravis as it interferes with pyridostigmine bromide effects 1

Given the absence of pediatric approval, lack of safety data in children, and potential for significant adverse effects, methocarbamol should not be prescribed for pediatric patients, according to the Mayo Clinic Proceedings 1

Do not use methocarbamol in patients with compromised hepatic or renal function without appropriate dose adjustment considerations 1